keyword
MENU ▼
Read by QxMD icon Read
search

ovarian cancer cytoreduction

keyword
https://www.readbyqxmd.com/read/29134372/systematic-review-of-cytoreductive-surgery-and-bevacizumab-containing-chemotherapy-in-advanced-ovarian-cancer-focus-on-safety
#1
REVIEW
Marco Petrillo, Camilla Nero, Vittoria Carbone, Matteo Bruno, Giovanni Scambia, Anna Fagotti
BACKGROUND: Initial experiences reported increased surgical morbidities in patients receiving cytoreductive surgery for colorectal cancer after bevacizumab-containing chemotherapy; however, more recent literature suggests a favorable toxicity profile in patients with advanced ovarian cancer (AOC). With the aim of providing a more objective point of view on this controversial issue, we present here a systematic literature review. METHODS: Systematic revision of the available literature was conducted using the PubMed, MEDLINE, and EMBASE electronic databases...
November 13, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29129391/centralization-of-ovarian-cancer-in-the-netherlands-hospital-of-diagnosis-no-longer-determines-patients-probability-of-undergoing-surgery
#2
Maite Timmermans, Melinda S Schuurman, Vincent K Y Ho, Leon F Massuger, Hans W Nijman, Toon van Gorp, Gabe S Sonke, Roy F P M Kruitwagen, Maaike A van der Aa
OBJECTIVE: Surgical care for advanced stage epithelial ovarian cancer (EOC) patients has been centralized in the Netherlands since 2012. We evaluated whether the likelihood for patients to undergo surgery depends on the hospital of initial diagnosis before and after centralization of surgical care. METHODS: Patients with EOC FIGO stage IIB-IV, diagnosed in the Netherlands between 2000 and 2015, were identified from the Netherlands Cancer Registry. Multilevel multivariate logistic regression was used to study the association between hospital of diagnosis and patients' likelihood of undergoing surgery in subsequent time periods...
November 9, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/29128106/who-are-the-long-term-survivors-of-high-grade-serous-ovarian-cancer
#3
REVIEW
Claire Hoppenot, Mark A Eckert, Samantha M Tienda, Ernst Lengyel
Although the median survival for epithelial ovarian cancer (EOC) is <5years, approximately 15% of patients will survive for >10years. A better understanding of these exceptional responders could reveal opportunities to improve the dismal prognosis of most EOC patients. In this review, we examine the clinical and genomic features that have been associated with long-term survival, which is generally defined as survival of >7-10years after initial diagnosis. Clinical features influencing long-term survival have been best reported in large retrospective population-based studies...
November 8, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/29128105/factors-associated-with-delivery-of-neoadjuvant-chemotherapy-in-women-with-advanced-stage-ovarian-cancer
#4
Emily Hinchcliff, Alexander Melamed, Amy Bregar, Elisabeth Diver, Joel Clemmer, Marcela Del Carmen, John O Schorge, J Alejandro Rauh-Hain
PURPOSE: To identify clinical and non-clinical factors associated with utilization of primary cytoreductive surgery (PCS) or neoadjuvant chemotherapy (NACT) in women with advanced stage epithelial ovarian cancer (EOC). METHODS: Using the National Cancer Database, we identified women with stage IIIC and IV EOC diagnosed from 2012 to 2014. The primary outcome was receipt of NACT, defined in the primary analysis as utilization of chemotherapy as the first cancer-directed therapy, irrespective of whether interval surgery was performed...
November 8, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/29121779/image-guided-surgery-in-gynecologic-oncology
#5
Henri Azaïs, Geoffroy Canlorbe, Yohan Kerbage, Anne Grabarz, Pierre Collinet, Serge Mordon
Image-guided surgery is a relevant way to reduce surgical morbidity and maximize cytoreductive surgery approach especially in ovarian cancer. Sentinel lymph node detection is a promising approach to avoid radical lymph node dissection and is slightly becoming standard in daily practice in endometrial and cervical cancer surgery even if it needs to be evaluated more precisely. Regarding carcinomatosis of ovarian origin, detection and treatment of microscopic disease could be appropriate to avoid local recurrences...
November 10, 2017: Future Oncology
https://www.readbyqxmd.com/read/29117194/a-pre-operative-predictive-score-to-evaluate-the-feasibility-of-complete-cytoreductive-surgery-in-patients-with-epithelial-ovarian-cancer
#6
Marion Chesnais, Fabrice Lecuru, Myriam Mimouni, Charlotte Ngo, Arnaud Fauconnier, Cyrille Huchon
OBJECTIVE: Postoperative residual tumor is the major prognostic factor in ovarian cancer. The feasibility of complete cytoreductive surgery is assessed by laparoscopy. Our goal was to develop a predictive score prior to laparoscopy to evaluate the feasibility of complete cytoreductive surgery in patients with epithelial ovarian cancer. METHODS: We developed a score to predict incomplete cytoreductive surgery by performing multiple logistic regressions after bootstrap procedures on data from a retrospective cohort of 247 patients with advanced ovarian cancer...
2017: PloS One
https://www.readbyqxmd.com/read/29113651/the-role-of-f18-fdg-pet-ct-in-predicting-secondary-optimal-de-bulking-in-patients-with-recurrent-ovarian-cancer
#7
Amnon Amit, Adina Hodes, Ofer Lavie, Zohar Keidar, Emad Matanes, Lior Lowenstein
BACKGROUND AND OBJECTIVES: The decision to perform secondary cytoreductive surgery for recurrent ovarian cancer is generally determined by clinical criteria. The aim of this study was to assess the predictive capability of FDG-PET/CT in identifying patients for whom secondary optimal debulking can be obtained. METHODS: We reviewed the records of all women with suspected recurrent ovarian cancer (CA-125 levels >35 U/ml and/or clinical symptoms), at two medical centers, between January 2004 and December 2013...
December 2017: Surgical Oncology
https://www.readbyqxmd.com/read/29081384/secondary-laparoscopic-cytoreduction-in-recurrent-ovarian-cancer-a-large-single-institution-experience
#8
Gallotta Valerio, Conte Conte, Giudice Maria Teresa, Nero Camilla, Vizzielli Giuseppe, Gueli Alletti Salvatore, Cianci Stefano, Lodoli Claudio, Di Giorgio Andrea, De Rose Agostino Maria, Fagotti Anna, Scambia Giovanni, Ferrandina Gabriella
STUDY OBJECTIVE: To analyze the feasibility and safety of laparoscopic secondary cytoreductive surgery in a retrospective series of platinum sensitive recurrent ovarian cancer patients. DESIGN: Retrospective cohort study (Canadian Task Force classification II-2). SETTING: Catholic University of the Sacred Hearth, Rome, Italy. PATIENTS: Between October 2010 and October 2016, 58 patients with recurrent ovarian cancer were selected for a retrospective analysis of data...
October 25, 2017: Journal of Minimally Invasive Gynecology
https://www.readbyqxmd.com/read/29064913/the-impact-of-number-of-cycles-of-neoadjuvant-chemotherapy-on-survival-of-patients-undergoing-interval-debulking-surgery-for-stage-iiic-iv-unresectable-ovarian-cancer-results-from-a-multi-institutional-study
#9
Giorgio Bogani, Laura Matteucci, Stefano Tamberi, Valentina Arcangeli, Antonino Ditto, Giuseppa Maltese, Mauro Signorelli, Fabio Martinelli, Valentina Chiappa, Umberto Leone Roberti Maggiore, Stefania Perotto, Cono Scaffa, Giuseppe Comerci, Marco Stefanetti, Francesco Raspagliesi, Domenica Lorusso
OBJECTIVES: Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) may be a valuable treatment option in advanced ovarian cancer when primary cytoreduction is not feasible. However, a consensus on the ideal number of NACT cycles is still lacking. In the present investigation, we aimed to evaluate how number of cycles of NACT influenced patients' outcomes. METHODS: Data of consecutive patients undergoing NACT and IDS were retrospectively reviewed in 4 Italian centers, and survival outcomes were evaluated...
November 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29059209/neoadjuvant-chemotherapy-versus-primary-debulking-surgery-in-advanced-epithelial-ovarian-cancer-a-meta-analysis-of-peri-operative-outcome
#10
Lijuan Yang, Bo Zhang, Guangyang Xing, Jingran Du, Bin Yang, Qianqian Yuan, Yongxiu Yang
OBJECTIVE: To assess whether neoadjuvant chemotherapy (NACT) is superior to primary debulking surgery (PDS) with regard to optimal cytoreduction, peri-operative morbidity, mortality, and quality of life (QOL) in advanced epithelial ovarian cancer (EOC). METHODS: We searched the PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, Registers of Clinical Trials for randomized controlled trials (RCTs) comparing NACT to PDS in women with Federation of International Gynaecologists and Obstetricians stage Ⅲ-Ⅳ EOC...
2017: PloS One
https://www.readbyqxmd.com/read/29055648/prognostic-factors-in-patients-undergoing-primary-cytoreductive-surgery-for-figo-stage-iiic-ovarian-tubal-or-peritoneal-cancer
#11
Alpaslan Kaban, Samet Topuz, Pınar Saip, Hamdullah Sözen, Yavuz Salihoğlu
OBJECTIVE: The aim of the study is to investigate factors related to overall survival in advanced stage ovarian, tubal, or peritoneal cancer and to identify strong and weak prognostic factors. METHODS: We retrospectively reviewed 190 patients who underwent primary cytoreductive surgery between 2003 and 2013. RESULTS: Median overall survival duration was founded 58 months (95% CI 49-67). Five-year overall survival ratio was 48.5%. Presence of tumour at upper abdomen, suboptimal cytoreduction (residual >1 cm), surgery without lymphadenectomy, and presence of peritoneal ascites more than 1 L had a significantly negative effect on overall survival, but not histological grade and CA-125 level, by univariate Cox analysis...
October 18, 2017: Journal of Obstetrics and Gynaecology Canada: JOGC, Journal D'obstétrique et Gynécologie du Canada: JOGC
https://www.readbyqxmd.com/read/29052073/laparoscopy-for-primary-cytoreduction-with-multivisceral-resections-in-advanced-ovarian-cancer-prospective-validation-the-times-they-are-a-changin
#12
Marcello Ceccaroni, Giovanni Roviglione, Francesco Bruni, Roberto Clarizia, Giacomo Ruffo, Matteo Salgarello, Michele Peiretti, Stefano Uccella
BACKGROUND: Primary cytoreduction is the mainstay of treatment for advanced ovarian cancer (AOC). We developed and prospectively evaluated an algorithm to investigate the possible role of laparoscopic primary cytoreduction (LPC) in carefully selected patients, with AOC. METHODS: From June 2007 to July 2015, all patients with stage III-IV ovarian cancer and clinical conditions allowing aggressive surgery were candidate to primary cytoreduction with the aim of achieving residual tumor (RT) = 0...
October 19, 2017: Surgical Endoscopy
https://www.readbyqxmd.com/read/29049607/dose-response-association-of-cd8-tumor-infiltrating-lymphocytes-and-survival-time-in-high-grade-serous-ovarian-cancer
#13
Ellen L Goode, Matthew S Block, Kimberly R Kalli, Robert A Vierkant, Wenqian Chen, Zachary C Fogarty, Aleksandra Gentry-Maharaj, Aleksandra Toloczko, Alexander Hein, Aliecia L Bouligny, Allan Jensen, Ana Osorio, Andreas D Hartkopf, Andy Ryan, Anita Chudecka-Glaz, Anthony M Magliocco, Arndt Hartmann, Audrey Y Jung, Bo Gao, Brenda Y Hernandez, Brooke L Fridley, Bryan M McCauley, Catherine J Kennedy, Chen Wang, Chloe Karpinskyj, Christiani B de Sousa, Daniel G Tiezzi, David L Wachter, Esther Herpel, Florin Andrei Taran, Francesmary Modugno, Gregg Nelson, Jan Lubinski, Janusz Menkiszak, Jennifer Alsop, Jenny Lester, Jesús García-Donas, Jill Nation, Jillian Hung, José Palacios, Joseph H Rothstein, Joseph L Kelley, Jurandyr M de Andrade, Luis Robles-Díaz, Maria P Intermaggio, Martin Widschwendter, Matthias W Beckmann, Matthias Ruebner, Mercedes Jimenez-Linan, Naveena Singh, Oleg Oszurek, Paul R Harnett, Peter F Rambau, Peter Sinn, Philipp Wagner, Prafull Ghatage, Raghwa Sharma, Robert P Edwards, Roberta B Ness, Sandra Orsulic, Sara Y Brucker, Sharon E Johnatty, Teri A Longacre, Ursula Eilber, Valerie McGuire, Weiva Sieh, Yanina Natanzon, Zheng Li, Alice S Whittemore, Anna deFazio, Annette Staebler, Beth Y Karlan, Blake Gilks, David D Bowtell, Estrid Høgdall, Francisco J Candido Dos Reis, Helen Steed, Ian G Campbell, Jacek Gronwald, Javier Benítez, Jennifer M Koziak, Jenny Chang-Claude, Kirsten B Moysich, Linda E Kelemen, Linda S Cook, Marc T Goodman, María José García, Peter A Fasching, Stefan Kommoss, Suha Deen, Susanne K Kjaer, Usha Menon, James D Brenton, Paul D P Pharoah, Georgia Chenevix-Trench, David G Huntsman, Stacey J Winham, Martin Köbel, Susan J Ramus
Importance: Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8+ TILs by histotype and in relation to other clinical factors. Objective: To define the prognostic role of CD8+ TILs in epithelial ovarian cancer. Design, Setting, and Participants: This was a multicenter observational, prospective survival cohort study of the Ovarian Tumor Tissue Analysis Consortium...
October 12, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/29046901/chirurgia-e-management-delle-pazienti-anziane-affette-da-carcinoma-ovarico
#14
Paolo Scollo, Giuseppe Scibilia, Basilio Pecorino
The median life expectancy of population among industrialized countries has dramatically expanded in recent years. On the other hand, the risk of developing cancer increases with age.The treatment for gynaecological malignancies is well defined with respect to the surgery, radiation treatment and chemotherapy. However, elderly patients receives substandard treatment when compared to the younger people, generally due to the presence of associated medical conditions. The assessment of the co-morbidity is an important aspect of the surgical decision-making process...
2017: Argom Oncol Geriatr
https://www.readbyqxmd.com/read/29042795/significant-association-of-the-exo1-rs851797-polymorphism-with-clinical-outcome-of-ovarian-cancer
#15
Tingyan Shi, Rong Jiang, Pan Wang, Yuan Xu, Sheng Yin, Xi Cheng, Rongyu Zang
BACKGROUND: Exonuclease 1 (EXO1), one of DNA mismatch repair pathway genes, functions in maintaining genomic stability and affects tumor progression. We hypothesized that genetic variations in EXO1 may predict clinical outcomes in epithelial ovarian cancer (EOC). METHODS: In this cohort study with 1,030 consecutive EOC patients, we genotyped four potentially functional polymorphisms in EXO1 by the Taqman assay and evaluated their associations with patients' survival...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29034309/metastatic-uterine-tumor-resembling-ovarian-sex-cord-tumor-a-case-report-and-review-of-the-literature
#16
Michelle L Kuznicki, Sharon E Robertson, Ardeshir Hakam, Mian M Shahzad
Uterine tumors resembling ovarian sex cord tumors (UTROSCTs) are rare and commonly characterized as benign tumors, with infrequent reports of metastasis and recurrence. Treatment recommendations have not been well established, particularly for more advanced cases. We present the first reported death from a metastatic UTROSCT, summarize the available literature, and describe characteristics common to UTROSCTs with aggressive features. In this case, a 49-year-old woman presented with abdominal distension and pain; initial imaging and diagnostic workup suggested metastatic epithelial ovarian cancer to be the cause...
November 2017: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/29018838/adverse-post-operative-outcomes-in-jehovah-s-witnesses-with-gynecologic-cancer-within-30%C3%A2-days-of-surgery-a-single-institution-review-of-36-cases
#17
Laura J Moulton, Peter G Rose, Haider Mahdi
Rates of blood transfusion are reported as high as 32% in women undergoing major gynecologic cancer surgery. Therefore, care of the gynecologic oncology patient who refuses blood products, such as Jehovah's witnesses, can pose a unique challenge. The objective of this study was to determine rate of adverse post-operative outcomes within 30 days of surgery in Jehovah's witnesses with gynecologic cancer. This was a retrospective cohort study of Jehovah's witnesses undergoing laparotomy or minimally invasive surgery (MIS) for gynecologic cancer at a single institution...
November 2017: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/29017822/sub-optimal-primary-surgery-leads-to-unfavorable-immunological-changes-in-ovarian-cancer-patients
#18
Marek Nowak, Ewa Głowacka, Przemysław Lewkowicz, Małgorzata Banasik, Krzysztof Szyłło, Kinga Zimna, Katarzyna Bednarska, Magdalena Klink
Primary cytoreduction, followed by chemotherapy, is a standard treatment of patients with epithelial ovarian cancer (EOC). However, the effectiveness of this treatment depend on various elements e.g. type of operation. It is accepted that optimal surgery correlates with longer survival of patients. The other element, an efficiency of immune system after surgical intervention although important is less elucidated. The aim of this study was to establish the impact of optimal and sub-optimal operation on immunological status of EOC patients regarding also their overall survival (OS)...
January 2018: Immunobiology
https://www.readbyqxmd.com/read/28988028/intensive-care-admissions-among-ovarian-cancer-patients-treated-with-primary-debulking-surgery-and-neoadjuvant-chemotherapy-interval-debulking-surgery
#19
Kristen Pepin, Amy Bregar, Michelle Davis, Alexander Melamed, Emily Hinchcliff, Allison Gockley, Neil Horowitz, Marcela G Del Carmen
OBJECTIVE: Admissions to intensive care units (ICU) are costly, but are necessary for some patients undergoing radical cancer surgery. When compared to primary debulking surgery (PDS), neoadjuvant chemotherapy (NACT) with interval debulking surgery, is associated with less peri-operative morbidity. In this study, we compare rates, indications and lengths of ICU stays among ovarian cancer patients admitted to the ICU within 30days of cytoreduction, either primary or interval. METHODS: A retrospective chart review was performed of patients with stage III-IV ovarian cancer who underwent surgical cytoreduction at two large academic medical centers between 2010 and 2014...
October 4, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28982890/debulking-surgery-for-clear-cell-carcinoma-of-the-ovary-a-case-report-and-literature-review
#20
REVIEW
Nicolae Bacalbasa, Irina Balescu, Alexandru Filipescu
Ovarian clear cell carcinoma represents a distinct histopathological subtype of epithelial ovarian cancer, with poor outcomes, especially in cases diagnosed in advanced stages of disease. However, even in these cases, it seems that the most effective treatment remains debulking surgery to no residual disease. We present the case of a 56-year-old patient diagnosed with a large pelvic mass invading the rectosigmoidal colon, and ileal loop who was successfully submitted to cytoreductive surgery to no residual disease...
October 2017: Anticancer Research
keyword
keyword
111476
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"